Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College of Medicine, who discussed his team's model predicting the changing prevalence of liver diseases in the U.S. until 2050. Dr. Zobair Younossi, the Global NASH Council Chairman, presented the latest findings on the correlation between food insecurity and MAFLD in American adolescents. Additionally, Dr. Rohit Loomba shared insights into the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD) and the challenges associated with it.
AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

From November 10th to 14th, the annual highlight of hepatology, the American Association for the Study of Liver Diseases (AASLD) 2023, was grandly held in Boston, USA. With over 200 abstracts from Chinese experts and scholars selected for oral presentations or poster sessions, the achievements were commendable. Congratulations to all! Dr. Fengmin Lu's team from Peking University has three contributions to this event (1 oral presentation and 2 posters). Today, we'll share insights from one of the posters presented on the first day, November 10th, revealing the team's academic prowess. The research discovered that the A1762T/G1764A mutation, by affecting the HBV transcriptome, can promote HBV replication (Abstract Number: 1514-C).
AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

From November 10th to 14th, the annual international event in hepatology—the American Association for the Study of Liver Diseases (AASLD) 2023—was grandly held in Boston, USA. According to incomplete statistics, more than 200 abstracts from Chinese experts and scholars were selected for oral presentations or poster exchanges at this conference, achieving fruitful results. Congratulations are extended here! The Beijing University People's Hospital and Peking University Hepatology Institute team achieved 1 oral and 9 poster presentations on scientific research in the fields of hepatic encephalopathy, fatty liver, hepatitis C, hepatitis B, and liver cancer. Some research abstracts are shared below, and "Hepatology Digest" takes you to appreciate the team's excellence.
AASLD Review | New Therapies for Hepatitis B: Vebicorvir, Selgantolimod, Bepirovirsen, Therapeutic Vaccines, and More

AASLD Review | New Therapies for Hepatitis B: Vebicorvir, Selgantolimod, Bepirovirsen, Therapeutic Vaccines, and More

Currently, some patients with chronic hepatitis B (CHB) can achieve clinical cure through interferon-based antiviral treatment. To pursue clinical cure for a larger population, there is a flurry of activity in the development of new drugs. Six studies on new therapies for hepatitis B were selected for presentation at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, to be discussed in the "Hepatitis B: New Therapies for HBV and HDV" session. Hepatology Digest has compiled this information for interested readers, and the session is scheduled for online access on November 12th at 8:30 AM local time.